Switzerland · Delayed Price · Currency is CHF Helvetia Baloise Holding AG Earnings Call Transcripts
Fiscal Year 2026
-
The group is executing a disciplined integration of Helvetia and Baloise, targeting CHF 650 million in run-rate savings and 10%-12% annual EPS growth through 2028. Strong market positions in Switzerland and Germany, robust capital, and a focus on AI-driven efficiency underpin ambitious financial and operational targets.
Fiscal Year 2025
-
Both companies delivered strong 2025 results, each achieving 20% earnings or profit growth and improved combined ratios. The merger led to a robust combined SST ratio of 260% and a proposed dividend increase of 5.54%.
-
The merger has closed with integration progressing smoothly and management teams in place. Significant accounting impacts from IFRS 17 include goodwill and intangible assets, but these do not affect cash or dividends. Synergies of CHF 350 million and a 20% dividend uplift by 2029 are targeted.
-
Underlying earnings rose 5% to CHF 301 million and net income surged 24% to CHF 320 million, driven by technical excellence and improved non-life underwriting. The group remains on track for its three-year targets and is progressing with the Baloise merger, while maintaining strong capital and operational efficiency.
-
The merger creates Switzerland’s second largest insurance group, targeting CHF 350 million in annual cost synergies and a 20% dividend capacity uplift by 2029. Integration is planned to complete by end-2028, with strong management alignment and a focus on sustainable growth.
Fiscal Year 2024
-
Underlying earnings surged 42% to CHF 529 million, with strong non-life and fee business growth, improved combined ratio, and a 6% dividend increase proposed. The group remains well-capitalized, with a 290% SST ratio and ambitious new targets for efficiency and profitability.
-
A new strategy targets 9%-11% EPS growth and 13%-16% ROE by 2027, driven by margin improvement, cost savings, and profitable growth across all segments. Integration in Spain, AI-driven efficiency, and a focus on Specialty Markets and the 50+ segment underpin ambitions, with over CHF 1.2 billion in dividends planned.
-
Solid H1 2024 results with underlying earnings of CHF 285 million, ROE at 13.4%, and strong capitalization (SST ~300%). Growth driven by non-life and capital-light life products, with improved technical profitability and fee income up 10.4%.